       Document 1196
 DOCN  M94A1196
 TI    Severe thrombocytopenia (ST) in HIV-1+ pts.
 DT    9412
 AU    Maiello A; Sciandra M; Sinicco A; Inst. Infect. Diseases, Univ. Turin,
       Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):187 (abstract no. PB0763). Unique
       Identifier : AIDSLINE ICA10/94371379
 AB    OBJECTIVE: to estimate the prevalence of ST (PTLs < 40,000/microliter)
       and the risk of developing spontaneous haemorragic manifestations (HM)
       in HIV1+. METHODS: from Feb. '85 to Oct. '93 we studied all the HIV1+
       pts with ST. Pts with HIV1 unrelated ST were excluded from the study.
       RESULTS: the study gathered 1250 HIV1+ (907 IDUs, 26 homo, 71 hetero, 12
       blood recipients; mean age 28.7 +/- 9.4 yr); 52 HIV1+ (5.4%) had a ST
       (mean PTL value: 21,600 +/- 11,000/microliter). Eleven of 52 pts (21.1%)
       had at least one HM episode (5 nose bleeding, 3 orthostatic purpura, 2
       ulaemorrhagia, 1 petechial lesion and haematuria). Their mean PTL value
       was 15,000 +/- 8900/microliter), whilst the mean PTL value of non-HM was
       22,000 +/- 10,700/microliter (p = NS). Among the study group, the mean
       CD4+ cell count was 398 +/- 318/microliter. The mean CD4+ cell count in
       HM was 303 +/- 125/microliter and 408 +/- 125/microliter in non-HM (p =
       NS). No significant correlation was seen between ST and age, stage of
       HIV1 infection and progression to AIDS. AZT was given to 19 pts: 7
       (36.8%) had persistent PTL increase. Relative risk of HM was 7.9 (95% CL
       4.2-14.8) in ST pts with HM. CONCLUSION: our data suggest that severe HM
       is an infrequent event. AZT is only of partial efficacy.
 DE    Acquired Immunodeficiency Syndrome/*BLOOD/COMPLICATIONS/DRUG  THERAPY
       Adult  Female  Hemorrhage/*EPIDEMIOLOGY/ETIOLOGY  Human  HIV
       Seropositivity/*BLOOD/COMPLICATIONS/DRUG THERAPY  *HIV-1  Leukocyte
       Count  Male  Retrospective Studies  Thrombocytopenia/*COMPLICATIONS  T4
       Lymphocytes  Zidovudine/THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

